USA flag logo/image

An Official Website of the United States Government

Arterial Cannula with Permissive Distal Perfusion

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75788
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
HL079742
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Michigan Critical Care Consultants, Inc.
3550 West Liberty Suite 3 Ann Arbor, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Arterial Cannula with Permissive Distal Perfusion
Agency: HHS
Contract: 2R44HL079742-02A1
Award Amount: $748,630.00
 

Abstract:

DESCRIPTION (provided by applicant): A novel cannula design is proposed to provide distal perfusion during arterial cannulation. Arterial cannulation is common in several applications of extracorporeal blood processing, such as ArterioVenous Carbon Dioxide Removal (AVCO2R) treatment. AVCO2R is a respiratory treatment that uncouples oxygenation from CO2 removal by utilizing a low-resistance gas exchanger in a simple percutaneous arteriovenous shunt (i.e. pumpless) to achieve near-total extracorporeal removal of CO2 production. As in all extracorporeal applications that require arterial cannulation, complications such as infection and distal ischemia can occur. A unique distal perfusion cannula (DPC) is presented, where a 3-section balloon incorporated at the tip of the cannula acts as a vessel support, as well as a variable flow controller that ensures and regulates distal flow. This design approach allows for the cannula size to be maximized, which minimizes the resistance of the extracorporeal circuit, while ensuring safety for the patient. The DPC described here offers a simple, adjustable solution to femoral cannulation and will hold the key to the adoption and efficacy of AVCO2R, as well as other extracorporeal support therapies. In Phase I, computational techniques and in vitro experiments were used to design the distal perfusion cannula (DPC), and to fully characterize the prototypes. A functional, 3-section balloon prototype has been completed and verified of its ability to optimize both distal and cannu la perfusion. The objective of Phase II is to construct a clinical quality DPC, and to verify that the cannula is successful in optimizing distal flow while minimizing complications on an in vivo animal model. At Phase II conclusion, manufacturability of t he DPC will be defined, and the long-term functionality of the device will be determined. This grant will result in the development of a novel distal perfusion cannula (DPC) for use in arterial cannulation. The new DPC will optimize the performance of an e xtracorporeal circuit, while ensuring safety for the patient.

Principal Investigator:

Kathryn R. Osterholzer
7349959089
KOSTER@MC3CORP.COM

Business Contact:

Melissa M. Reynolds
koster@mc3corp.com
Small Business Information at Submission:

MC3, INC.
MC3, INC. 3550 W LIBERTY RD, STE 3 ANN ARBOR, MI 48103

EIN/Tax ID: 382667222
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No